Literature DB >> 33317804

Prospective clinical validation of the Eleveld propofol pharmacokinetic-pharmacodynamic model in general anaesthesia.

Remco Vellinga1, Laura N Hannivoort2, Michele Introna3, Daan J Touw4, Anthony R Absalom2, Douglas J Eleveld2, Michel M R F Struys5.   

Abstract

BACKGROUND: Target-controlled infusion (TCI) systems incorporating pharmacokinetic (PK) or PK-pharmacodynamic (PK-PD) models can be used to facilitate drug administration. Existing models were developed using data from select populations, the use of which is, strictly speaking, limited to these populations. Recently a propofol PK-PD model was developed for a broad population range. The aim of the study was to prospectively validate this model in children, adults, older subjects, and obese adults undergoing general anaesthesia.
METHODS: The 25 subjects included in each of four groups were stratified by age and weight. Subjects received propofol through TCI with the Eleveld model, titrated to a bispectral index (BIS) of 40-60. Arterial blood samples were collected at 5, 10, 20, 30, 40, and 60 min after the start of propofol infusion, and every 30 min thereafter, to a maximum of 10 samples. BIS was recorded continuously. Predictive performance was assessed using the Varvel criteria.
RESULTS: For PK, the Eleveld model showed a bias < ±20% in children, adults, and obese adults, but a greater bias (-27%) in older subjects. Precision was <30% in all groups. For PD, the bias and wobble were <5 BIS units and the precision was close to 10 BIS units in all groups. Anaesthetists were able to achieve intraoperative BIS values of 40-60 using effect-site target concentrations about 85-140% of the age-adjusted Ce50.
CONCLUSIONS: The Eleveld propofol PK-PD model showed predictive precision <30% for arterial plasma concentrations and BIS predictions with a low (population) bias when used in TCI in clinical anaesthesia practice.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  pharmacodynamics; pharmacokinetic-pharmacodynamic model; pharmacokinetics; plasma concentration; propofol; target-controlled infusion

Mesh:

Substances:

Year:  2020        PMID: 33317804     DOI: 10.1016/j.bja.2020.10.027

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  8 in total

1.  Humidity and measurement of volatile propofol using MCC-IMS (EDMON).

Authors:  Tobias Teucke; F Maurer; L M Müller-Wirtz; T Volk; D I Sessler; S Kreuer
Journal:  J Clin Monit Comput       Date:  2022-09-21       Impact factor: 1.977

Review 2.  What's New in Intravenous Anaesthesia? New Hypnotics, New Models and New Applications.

Authors:  Remco Vellinga; Beatrijs I Valk; Anthony R Absalom; Michel M R F Struys; Clemens R M Barends
Journal:  J Clin Med       Date:  2022-06-17       Impact factor: 4.964

Review 3.  General Purpose Pharmacokinetic-Pharmacodynamic Models for Target-Controlled Infusion of Anaesthetic Drugs: A Narrative Review.

Authors:  Ophélie Vandemoortele; Laura N Hannivoort; Florian Vanhoorebeeck; Michel M R F Struys; Hugo E M Vereecke
Journal:  J Clin Med       Date:  2022-04-28       Impact factor: 4.964

4.  Reply to: Comment on: Variation in propofol induction doses administered to surgical patients over 65.

Authors:  Shamsuddin Akhtar; Amit Bardia; Robert B Schonberger
Journal:  J Am Geriatr Soc       Date:  2021-06-29       Impact factor: 7.538

Review 5.  Bayesian statistics in anesthesia practice: a tutorial for anesthesiologists.

Authors:  Michele Introna; Johannes P van den Berg; Douglas J Eleveld; Michel M R F Struys
Journal:  J Anesth       Date:  2022-02-11       Impact factor: 2.931

6.  Online exhaled propofol monitoring in normal-weight and obese surgical patients.

Authors:  Martin R Braathen; Ivan Rimstad; Terje Dybvik; Ståle Nygård; Johan Raeder
Journal:  Acta Anaesthesiol Scand       Date:  2022-02-19       Impact factor: 2.274

7.  Propofol Suppresses Cell Progression by Inhibiting CCL18 Expression in Hepatoblastoma.

Authors:  Hua Zhang; Pingling Lin; Lei Fu; Zhijun Li; Yan Ding
Journal:  J Oncol       Date:  2021-07-26       Impact factor: 4.375

8.  ST-Segment Elevation, Brugada Syndrome, and Propofol?: Is This the Only Thing We Should Be Noticing?

Authors:  Panagiotis Flamée; Hugo Carvalho; Patrice Forget
Journal:  JACC Case Rep       Date:  2022-01-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.